X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs CIPLA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD CIPLA ALEMBIC LTD/
CIPLA
 
P/E (TTM) x 75.7 43.5 173.9% View Chart
P/BV x 2.8 3.6 78.3% View Chart
Dividend Yield % 0.4 0.4 111.5%  

Financials

 ALEMBIC LTD   CIPLA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
CIPLA
Mar-17
ALEMBIC LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs53622 8.5%   
Low Rs29458 6.4%   
Sales per share (Unadj.) Rs4.7181.9 2.6%  
Earnings per share (Unadj.) Rs8.812.9 68.2%  
Cash flow per share (Unadj.) Rs9.029.3 30.7%  
Dividends per share (Unadj.) Rs0.152.00 7.5%  
Dividend yield (eoy) %0.40.4 98.7%  
Book value per share (Unadj.) Rs27.7155.7 17.8%  
Shares outstanding (eoy) m267.03804.51 33.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x8.73.0 292.8%   
Avg P/E ratio x4.742.0 11.1%  
P/CF ratio (eoy) x4.618.4 24.7%  
Price / Book Value ratio x1.53.5 42.7%  
Dividend payout %1.715.5 11.0%   
Avg Mkt Cap Rs m10,962434,516 2.5%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m23826,338 0.9%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m1,260146,302 0.9%  
Other income Rs m2642,287 11.5%   
Total revenues Rs m1,524148,589 1.0%   
Gross profit Rs m8324,758 0.3%  
Depreciation Rs m6113,229 0.5%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m28512,222 2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m2,096-70 -2,998.9%   
Extraordinary Inc (Exp) Rs m-320-   
Tax Rs m61,798 0.3%   
Profit after tax Rs m2,34310,354 22.6%  
Gross profit margin %6.616.9 38.8%  
Effective tax rate %2.114.7 14.6%   
Net profit margin %185.97.1 2,626.6%  
BALANCE SHEET DATA
Current assets Rs m1,68987,370 1.9%   
Current liabilities Rs m48633,081 1.5%   
Net working cap to sales %95.437.1 257.1%  
Current ratio x3.52.6 131.5%  
Inventory Days Days21787 249.5%  
Debtors Days Days8162 130.1%  
Net fixed assets Rs m1,624111,567 1.5%   
Share capital Rs m5341,609 33.2%   
"Free" reserves Rs m5,960123,645 4.8%   
Net worth Rs m7,404125,254 5.9%   
Long term debt Rs m10436,454 0.3%   
Total assets Rs m8,010209,532 3.8%  
Interest coverage x950.78.7 10,967.2%   
Debt to equity ratio x00.3 4.8%  
Sales to assets ratio x0.20.7 22.5%   
Return on assets %29.35.7 513.0%  
Return on equity %31.68.3 382.8%  
Return on capital %31.38.5 368.1%  
Exports to sales %2.934.2 8.6%   
Imports to sales %28.98.3 346.0%   
Exports (fob) Rs m3750,050 0.1%   
Imports (cif) Rs m36412,203 3.0%   
Fx inflow Rs m3751,066 0.1%   
Fx outflow Rs m36517,678 2.1%   
Net fx Rs m-32833,388 -1.0%   
CASH FLOW
From Operations Rs m34623,824 1.5%  
From Investments Rs m-48-13,127 0.4%  
From Financial Activity Rs m-301-13,239 2.3%  
Net Cashflow Rs m-3-2,478 0.1%  

Share Holding

Indian Promoters % 64.0 16.0 400.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.2 12.2 1.6%  
FIIs % 9.7 23.7 40.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.1 26.2 99.6%  
Shareholders   54,701 161,166 33.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  ABBOTT INDIA  PANACEA BIOTECH  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS